在治疗多肌痛性风湿症方面取得了进展
Luca Iorio1, Milena Bond2, Roberto Padoan1
1Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy.
Rheumatology (Oxford, England)
|March 12, 2025
概括
多发性肌痛性风湿症 (PMR) 治疗侧重于葡萄糖皮质类药物,但复发和毒性很常见. 新的生物药物和像治疗到标等策略为这种常见的炎症状况提供了更好的结果.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
背景情况:
- 多发性肌痛性风湿症 (PMR) 是50岁以上的个体普遍存在的炎症性疾病.
- 葡萄糖皮质类药物 (GCs) 是主要的治疗方法,但高复发率 (高达76%) 和显著的毒性 (高达85%) 限制了它们的长期使用.
- 传统的合成疾病修饰性抗风湿药物 (csDMARDs) 的疗效有限.
研究的目的:
- 审查当前和新兴的多肌痛性风湿症的治疗策略.
- 突出与葡萄糖皮质激素治疗相关的挑战和新药的潜力.
- 强调治疗到目标方法和专业管理的重要性.
主要方法:
- 关于多肌痛类风湿治疗的当前文献的综述.
- 对葡萄糖皮质类药物,csDMARDs和生物制剂的疗效和安全性的分析.
- 讨论新兴疗法,包括JAK抑制剂和B细胞枯竭.
主要成果:
- 葡萄糖皮质类药物是有效的,但与长期严重的毒性和复发率有关.
- 托西利祖马布和沙利祖马布等生物药物在减少GC依赖和实现缓解方面表现有前途.
- 新兴的治疗方法,如JAK抑制剂和B细胞枯竭,需要进一步验证.
结论:
- 包括生物药物和JAK抑制剂在内的新型治疗策略正在改变PMR管理.
- 治疗到目标的方法对于实现持续缓解和最大限度地减少不良影响至关重要.
- 专业的风湿学专业知识,早期转诊和标准化结果定义对于最佳的患者护理至关重要.
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
1.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.1K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
126
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
126
01:22Alzheimer's Disease: Treatment
141
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
141